Clinical Trials

A Phase 1b Multi-cohort Clinical Study of the Combination of Selumetinib (MK-5618) plus Pembrolizumab (MK-3475) alone or the Combination of Pembrolizumab plus Chemotherapy with or without MK-5618 in Participants with Metastatic Solid Tumors


Study ID
Merck MK-5618-001

NCT Number
NCT03833427 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0950

Principle Investigator
Dr. Martin Gutierrez

Phase
I

Sponsor
Merck


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now